MA44518A - Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin - Google Patents
Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoinInfo
- Publication number
- MA44518A MA44518A MA044518A MA44518A MA44518A MA 44518 A MA44518 A MA 44518A MA 044518 A MA044518 A MA 044518A MA 44518 A MA44518 A MA 44518A MA 44518 A MA44518 A MA 44518A
- Authority
- MA
- Morocco
- Prior art keywords
- subject
- needs
- angiogenesis inhibition
- inhibition processes
- processes
- Prior art date
Links
- 230000033115 angiogenesis Effects 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315857P | 2016-03-31 | 2016-03-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA44518A true MA44518A (fr) | 2019-02-06 |
Family
ID=59959191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA044518A MA44518A (fr) | 2016-03-31 | 2017-03-31 | Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US10870708B2 (fr) |
| EP (1) | EP3436072A4 (fr) |
| JP (3) | JP6865767B2 (fr) |
| KR (3) | KR20180128941A (fr) |
| CN (3) | CN115137816A (fr) |
| AU (2) | AU2017240129B2 (fr) |
| BR (1) | BR112018069732A2 (fr) |
| CA (2) | CA3096270C (fr) |
| CL (1) | CL2018002708A1 (fr) |
| EA (2) | EA201892218A1 (fr) |
| GE (1) | GEP20237466B (fr) |
| IL (2) | IL305200A (fr) |
| MA (1) | MA44518A (fr) |
| MX (2) | MX2018011648A (fr) |
| MY (1) | MY195432A (fr) |
| NZ (1) | NZ745531A (fr) |
| PH (1) | PH12018502046A1 (fr) |
| SG (2) | SG11201808242UA (fr) |
| WO (1) | WO2017173290A1 (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170170B1 (ar) | 2016-08-31 | 2022-09-15 | Omeros Corp | صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق |
| CN107661492A (zh) * | 2017-08-31 | 2018-02-06 | 中山大学中山眼科中心 | Vegf‑b的新用途 |
| CN107537026A (zh) * | 2017-08-31 | 2018-01-05 | 中山大学中山眼科中心 | Vegf‑b的应用 |
| US11584714B2 (en) | 2018-05-29 | 2023-02-21 | Omeros Corporation | MASP-2 inhibitors and methods of use |
| US12029940B2 (en) | 2019-03-11 | 2024-07-09 | Rom Technologies, Inc. | Single sensor wearable device for monitoring joint extension and flexion |
| US11904207B2 (en) | 2019-05-10 | 2024-02-20 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to present a user interface representing a user's progress in various domains |
| US11957956B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies, Inc. | System, method and apparatus for rehabilitation and exercise |
| US11433276B2 (en) | 2019-05-10 | 2022-09-06 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to independently adjust resistance of pedals based on leg strength |
| US11957960B2 (en) | 2019-05-10 | 2024-04-16 | Rehab2Fit Technologies Inc. | Method and system for using artificial intelligence to adjust pedal resistance |
| US12102878B2 (en) | 2019-05-10 | 2024-10-01 | Rehab2Fit Technologies, Inc. | Method and system for using artificial intelligence to determine a user's progress during interval training |
| US11896540B2 (en) | 2019-06-24 | 2024-02-13 | Rehab2Fit Technologies, Inc. | Method and system for implementing an exercise protocol for osteogenesis and/or muscular hypertrophy |
| US11071597B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Telemedicine for orthopedic treatment |
| US12062425B2 (en) | 2019-10-03 | 2024-08-13 | Rom Technologies, Inc. | System and method for implementing a cardiac rehabilitation protocol by using artificial intelligence and standardized measurements |
| US11101028B2 (en) | 2019-10-03 | 2021-08-24 | Rom Technologies, Inc. | Method and system using artificial intelligence to monitor user characteristics during a telemedicine session |
| US11915816B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | Systems and methods of using artificial intelligence and machine learning in a telemedical environment to predict user disease states |
| US11955222B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for determining, based on advanced metrics of actual performance of an electromechanical machine, medical procedure eligibility in order to ascertain survivability rates and measures of quality-of-life criteria |
| US11069436B2 (en) | 2019-10-03 | 2021-07-20 | Rom Technologies, Inc. | System and method for use of telemedicine-enabled rehabilitative hardware and for encouraging rehabilitative compliance through patient-based virtual shared sessions with patient-enabled mutual encouragement across simulated social networks |
| US11955220B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine for invasive surgical treatment to determine a cardiac treatment plan that uses an electromechanical machine |
| US11317975B2 (en) | 2019-10-03 | 2022-05-03 | Rom Technologies, Inc. | Method and system for treating patients via telemedicine using sensor data from rehabilitation or exercise equipment |
| US11887717B2 (en) | 2019-10-03 | 2024-01-30 | Rom Technologies, Inc. | System and method for using AI, machine learning and telemedicine to perform pulmonary rehabilitation via an electromechanical machine |
| US11075000B2 (en) | 2019-10-03 | 2021-07-27 | Rom Technologies, Inc. | Method and system for using virtual avatars associated with medical professionals during exercise sessions |
| US11923065B2 (en) | 2019-10-03 | 2024-03-05 | Rom Technologies, Inc. | Systems and methods for using artificial intelligence and machine learning to detect abnormal heart rhythms of a user performing a treatment plan with an electromechanical machine |
| US11961603B2 (en) | 2019-10-03 | 2024-04-16 | Rom Technologies, Inc. | System and method for using AI ML and telemedicine to perform bariatric rehabilitation via an electromechanical machine |
| US12020800B2 (en) | 2019-10-03 | 2024-06-25 | Rom Technologies, Inc. | System and method for using AI/ML and telemedicine to integrate rehabilitation for a plurality of comorbid conditions |
| US11978559B2 (en) | 2019-10-03 | 2024-05-07 | Rom Technologies, Inc. | Systems and methods for remotely-enabled identification of a user infection |
| US11955223B2 (en) | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning to provide an enhanced user interface presenting data pertaining to cardiac health, bariatric health, pulmonary health, and/or cardio-oncologic health for the purpose of performing preventative actions |
| US11955221B2 (en) * | 2019-10-03 | 2024-04-09 | Rom Technologies, Inc. | System and method for using AI/ML to generate treatment plans to stimulate preferred angiogenesis |
| US11915815B2 (en) | 2019-10-03 | 2024-02-27 | Rom Technologies, Inc. | System and method for using artificial intelligence and machine learning and generic risk factors to improve cardiovascular health such that the need for additional cardiac interventions is mitigated |
| US12020799B2 (en) | 2019-10-03 | 2024-06-25 | Rom Technologies, Inc. | Rowing machines, systems including rowing machines, and methods for using rowing machines to perform treatment plans for rehabilitation |
| JP2023504543A (ja) | 2019-12-04 | 2023-02-03 | オメロス コーポレーション | Ｍａｓｐ－２阻害剤および使用方法 |
| CA3159176A1 (fr) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Inhibiteurs de masp-2 et procedes d'utilisation |
| CA3159167A1 (fr) | 2019-12-04 | 2021-06-10 | Neil S. Cutshall | Inhibiteurs de masp-2 et procedes d'utilisation |
| WO2021113698A1 (fr) | 2019-12-04 | 2021-06-10 | Omeros Corporation | Inhibiteurs de masp-2 et procédés d'utilisation |
| US11107591B1 (en) | 2020-04-23 | 2021-08-31 | Rom Technologies, Inc. | Method and system for describing and recommending optimal treatment plans in adaptive telemedical or other contexts |
| US12100499B2 (en) | 2020-08-06 | 2024-09-24 | Rom Technologies, Inc. | Method and system for using artificial intelligence and machine learning to create optimal treatment plans based on monetary value amount generated and/or patient outcome |
| KR20220031412A (ko) | 2020-09-04 | 2022-03-11 | 주식회사 엘지에너지솔루션 | 배터리 관리 장치 및 방법 |
| CA3240483A1 (fr) | 2021-12-10 | 2023-06-15 | Thomas Dudler | Anticorps therapeutiques qui se lient au domaine serine protease de masp-2 et leurs utilisations |
| US20240228499A1 (en) | 2022-11-30 | 2024-07-11 | Omeros Corporation | Masp-2 inhibitors and methods of use |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5453566A (en) | 1986-03-28 | 1995-09-26 | Calgene, Inc. | Antisense regulation of gene expression in plant/cells |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| RO114469B1 (ro) | 1987-12-15 | 1999-04-30 | Gene Shears Pty Ltd | Compus oligoribonucleotidic, procedeu de preparare si metoda de inactivare |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8822492D0 (en) | 1988-09-24 | 1988-10-26 | Considine J | Apparatus for removing tumours from hollow organs of body |
| US5211657A (en) | 1988-11-07 | 1993-05-18 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| SG46445A1 (en) | 1990-01-26 | 1998-02-20 | Immunomedics Inc | Vaccines against cancer and infectious diseases |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| US5789573A (en) | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| IL108367A0 (en) | 1993-01-27 | 1994-04-12 | Hektoen Inst For Medical Resea | Antisense polynzcleotide inhibition of human growth factor-sensitive cancer cells |
| US5629327A (en) * | 1993-03-01 | 1997-05-13 | Childrens Hospital Medical Center Corp. | Methods and compositions for inhibition of angiogenesis |
| US5801154A (en) | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5739119A (en) | 1996-11-15 | 1998-04-14 | Galli; Rachel L. | Antisense oligonucleotides specific for the muscarinic type 2 acetylcholine receptor MRNA |
| US7083786B2 (en) * | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6649592B1 (en) | 2000-01-14 | 2003-11-18 | Science & Technology Corporation @ Unm | Peptide inhibitors of LFA-1/ICAM-1 interaction |
| SG98393A1 (en) | 2000-05-19 | 2003-09-19 | Inst Materials Research & Eng | Injectable drug delivery systems with cyclodextrin-polymer based hydrogels |
| JP4723244B2 (ja) | 2002-07-19 | 2011-07-13 | オメロス コーポレイション | 生分解性トリブロックコポリマー、その合成方法、ならびにそれから作製されるヒドロゲルおよび生体材料 |
| PT2374819T (pt) | 2003-05-12 | 2017-07-04 | Helion Biotech Aps | Anticorpos para masp-2 |
| US7919094B2 (en) * | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20130266559A1 (en) * | 2004-06-10 | 2013-10-10 | University Of Leicester | Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation |
| US8840893B2 (en) * | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US8168584B2 (en) | 2005-10-08 | 2012-05-01 | Potentia Pharmaceuticals, Inc. | Methods of treating age-related macular degeneration by compstatin and analogs thereof |
| US11130801B2 (en) * | 2011-01-13 | 2021-09-28 | Case Western Reserve University | Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies |
| CA3076975C (fr) | 2011-04-08 | 2024-06-18 | Omeros Corporation | Methodes de traitement d'etats associes a une activation du complement dependant dr masp-2 |
| CA3131223C (fr) * | 2011-05-04 | 2024-01-30 | Omeros Corporation | Compositions pour inhiber l'activation de complement dependant de masp-2 |
| AU2012272706B2 (en) * | 2011-06-22 | 2017-07-06 | Apellis Pharmaceuticals, Inc. | Methods of treating chronic disorders with complement inhibitors |
| EP3058951A1 (fr) | 2012-06-18 | 2016-08-24 | Omeros Corporation | Compositions et procédés d'inhibition de masp-1 et/ou masp-2 et/ou masp-3 pour le traitement de diverses maladies et troubles |
| SI3057993T1 (sl) * | 2013-10-17 | 2021-03-31 | Omeros Corporation | Postopki za zdravljenje bolezenskih stanj, povezanih z aktivacijo komplementov, odvisnih od MASP-2 |
| JP6369862B2 (ja) | 2014-08-06 | 2018-08-08 | 原 英彰 | 眼内血管新生抑制剤及びその用途 |
-
2017
- 2017-03-31 IL IL305200A patent/IL305200A/en unknown
- 2017-03-31 WO PCT/US2017/025411 patent/WO2017173290A1/fr active Application Filing
- 2017-03-31 EP EP17776787.8A patent/EP3436072A4/fr active Pending
- 2017-03-31 CN CN202210704608.7A patent/CN115137816A/zh active Pending
- 2017-03-31 GE GEAP201714913A patent/GEP20237466B/en unknown
- 2017-03-31 EA EA201892218A patent/EA201892218A1/ru unknown
- 2017-03-31 CN CN202311390678.0A patent/CN117582494A/zh active Pending
- 2017-03-31 CA CA3096270A patent/CA3096270C/fr active Active
- 2017-03-31 SG SG11201808242UA patent/SG11201808242UA/en unknown
- 2017-03-31 CN CN201780021420.XA patent/CN109152834A/zh active Pending
- 2017-03-31 CA CA3018774A patent/CA3018774C/fr active Active
- 2017-03-31 KR KR1020187030563A patent/KR20180128941A/ko not_active IP Right Cessation
- 2017-03-31 MX MX2018011648A patent/MX2018011648A/es unknown
- 2017-03-31 NZ NZ745531A patent/NZ745531A/en unknown
- 2017-03-31 US US15/476,154 patent/US10870708B2/en active Active
- 2017-03-31 KR KR1020237002512A patent/KR20230019991A/ko not_active Application Discontinuation
- 2017-03-31 KR KR1020207027488A patent/KR20200113290A/ko not_active Application Discontinuation
- 2017-03-31 EA EA202191185A patent/EA202191185A1/ru unknown
- 2017-03-31 AU AU2017240129A patent/AU2017240129B2/en active Active
- 2017-03-31 IL IL262021A patent/IL262021B2/en unknown
- 2017-03-31 MY MYPI2018001577A patent/MY195432A/en unknown
- 2017-03-31 BR BR112018069732A patent/BR112018069732A2/pt unknown
- 2017-03-31 JP JP2018551413A patent/JP6865767B2/ja active Active
- 2017-03-31 SG SG10202009886SA patent/SG10202009886SA/en unknown
- 2017-03-31 MA MA044518A patent/MA44518A/fr unknown
-
2018
- 2018-09-24 PH PH12018502046A patent/PH12018502046A1/en unknown
- 2018-09-24 MX MX2022012380A patent/MX2022012380A/es unknown
- 2018-09-25 CL CL2018002708A patent/CL2018002708A1/es unknown
-
2020
- 2020-03-05 AU AU2020201633A patent/AU2020201633B2/en active Active
- 2020-04-22 JP JP2020075784A patent/JP2020125332A/ja active Pending
- 2020-11-17 US US16/950,645 patent/US11981748B2/en active Active
-
2022
- 2022-05-27 JP JP2022086774A patent/JP2022110159A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA44518A (fr) | Procédés d'inhibition d'angiogenèse chez un sujet qui en a besoin | |
| DK3263782T3 (da) | Indløbselement | |
| IL249690A0 (en) | The clean collar sticker | |
| UA33118S (uk) | Підвіска «коловрат із зіркою русі» | |
| UA33327S (uk) | Ювелірний виріб «оберіг» | |
| UA34469S (uk) | Брошка «шаучам» | |
| GB201620146D0 (en) | Concept 36 A | |
| GB201620178D0 (en) | Concept 36 A | |
| UA33828S (uk) | Емблема «мегамастер» | |
| UA34208S (uk) | Пряжка «драккар» | |
| GB201620172D0 (en) | Concept 40 | |
| UA34203S (uk) | Підвіска «зігфрід» | |
| GB201613858D0 (en) | Concept 122 | |
| GB201613364D0 (en) | Concept 118 | |
| GB201613340D0 (en) | Concept 117 | |
| GB201613341D0 (en) | Concept 115 | |
| GB201613342D0 (en) | Concept 116 | |
| GB201612881D0 (en) | Concept 02 | |
| GB201612833D0 (en) | Concept 134 | |
| GB201612802D0 (en) | Concept 115 | |
| GB201612547D0 (en) | Concept 114 | |
| GB201612464D0 (en) | Concept 113 | |
| GB201612377D0 (en) | Concept 65 | |
| GB201612378D0 (en) | Concept 70 | |
| UA32360S (uk) | Логотип «f1» |